Cogent Biosciences (COGT) files mixed shelf
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Cogent (COGT) PT Raised to $50 at Leerink Partners
November 10, 2025 1:18 PM ESTLeerink Partners analyst Andrew Berens raised the price target on Cogent (NASDAQ: COGT) to $50.00 (from $18.00) while maintaining a Outperform rating.
The analyst comments "This morning, COGT announced topline results for the Ph 3 PEAK trial and hosted a conference call. As a reminder, PEAK evaluated the KIT inhibitor bezuclastinib (bezu) in combination with sunitinib vs sunitinib monotherapy in patients with gastrointerstinal stromal tumors (GIST) after progression on the 1L therapy imatinib. We view the results obtained in the 2L as offering unprecedented efficacy... More
Stifel Upgrades Cogent (COGT) to Buy
November 10, 2025 10:54 AM ESTStifel analyst Laura Prendergast upgraded Cogent (NASDAQ: COGT) from Hold to Buy with a price target of $40.00 (from $16.00).
The analyst comments "Today, COGT reported overwhelmingly positive results in the Ph3 PEAK study of bezuclastinib plus sunitinib vs. sunitinib alone in 2L GIST... More
